Jackson Wealth Management LLC Buys Shares of 4,114 Gilead Sciences, Inc. (NASDAQ:GILD)

Jackson Wealth Management LLC purchased a new stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,114 shares of the biopharmaceutical company's stock, valued at approximately $461,000.

Other institutional investors have also recently bought and sold shares of the company. Bridgewater Associates LP grew its holdings in Gilead Sciences by 122.7% during the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock worth $42,577,000 after acquiring an additional 253,994 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after buying an additional 14,009 shares during the last quarter. Ontario Teachers Pension Plan Board increased its stake in shares of Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after buying an additional 13,086 shares during the period. Mufg Securities Americas Inc. acquired a new position in shares of Gilead Sciences during the fourth quarter valued at $1,699,000. Finally, Capital International Inc. CA increased its position in Gilead Sciences by 23.8% in the fourth quarter. Capital International Inc. CA now owns 312,209 shares of the biopharmaceutical company's stock worth $28,839,000 after purchasing an additional 60,035 shares during the period. Institutional investors own 83.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on GILD. JPMorgan Chase & Co. increased their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a research note on Thursday, March 27th. Oppenheimer dropped their target price on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a report on Friday, April 25th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Cantor Fitzgerald started coverage on shares of Gilead Sciences in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on shares of Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $110.55.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 28,000 shares of the firm's stock in a transaction on Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider owned 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total transaction of $275,425.00. Following the completion of the transaction, the chief financial officer owned 165,110 shares of the company's stock, valued at $18,190,168.70. The trade was a 1.49% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 58,500 shares of company stock worth $6,340,745 in the last quarter. Corporate insiders own 0.27% of the company's stock.

Gilead Sciences Stock Performance

Shares of GILD stock traded down $0.24 during midday trading on Friday, hitting $111.28. 4,039,811 shares of the company were exchanged, compared to its average volume of 7,706,267. Gilead Sciences, Inc. has a 52 week low of $66.34 and a 52 week high of $119.96. The firm has a market capitalization of $138.42 billion, a P/E ratio of 23.43, a PEG ratio of 0.72 and a beta of 0.29. The firm's 50 day moving average price is $107.02 and its two-hundred day moving average price is $104.02. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion during the quarter, compared to the consensus estimate of $6.77 billion. During the same period last year, the business posted ($1.32) earnings per share. The business's revenue for the quarter was down .3% compared to the same quarter last year. As a group, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.84%. The ex-dividend date of this dividend was Friday, June 13th. Gilead Sciences's dividend payout ratio is currently 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.